Sachin D. Patel discloses substantial share acquisition in Gujarat Themis Biosyn under SEBI Takeover Code
Under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, Regulation 10(5) requires that when a person acquires shares crossing prescribed thresholds (5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%), a disclosure must be filed with the stock exchange within 2 trading days. Sachin D. Patel's filing with NSE indicates he has crossed one or more such thresholds. The timing (24 June 2026) and the identifiable acquirer suggest this is likely a single-purchaser acquisition in the pharmaceutical/biotech sector, now subject to public scrutiny and potential subsequent takeover obligations.
Why it mattersRegulation 10(5) disclosures mark critical shareholding milestones under the SEBI Takeover Code; the acquirer's identity, acquisition timing and quantum now trigger open-market scrutiny and potential competing bids or regulatory gating.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object]
Sources
- NSE Archives - Corporate Actions Filing · official
- SEBI Official - Master Circular on Takeover Regulations · official
- NSE Listing Agreement & Rules · official
Related deals
- Anupam Rasayan India acquires controlling stake in Bliss GVS Pharma; Kanga & Co advises sellers28 Oct 2026
- Fortis Healthcare Limited: Press Release28 Oct 2026 · ₹277 Cr
- Fortis Healthcare Limited: Acquisition28 Oct 2026
- ThinkLaw advises Jagsonpal Pharma on acquiring Group Pharma's wellness portfolio27 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026